Literature DB >> 4038513

Growth hormone secretory dynamics in Turner syndrome.

J L Ross, L M Long, D L Loriaux, G B Cutler.   

Abstract

We investigated whether a decrease in serum growth hormone contributes to the short stature of adults with Turner syndrome by measuring the 24-hour profile of serum growth hormone in 30 patients aged 2 to 20 years. Growth hormone pulses were defined as a rise from nadir to peak that exceeded three times the intraassay coefficient of variation. Girls with Turner syndrome aged 2 to 8 years did not have statistically different growth hormone levels, peak amplitudes, and peak frequencies compared with those in age-matched controls. By contrast, girls with Turner syndrome aged 9 to 20 years had significantly decreased mean 24-hour growth hormone levels, peak amplitudes, and peak frequencies compared with those in age-matched normal girls. Patients with Turner syndrome of all ages had decreased serum somatomedin-C concentrations and delayed bone ages. We conclude that a relative deficiency of growth hormone in pubertal patients with Turner syndrome may contribute to their adult short stature.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038513     DOI: 10.1016/s0022-3476(85)80287-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  A rational approach to short stature: focus on use and abuse of growth hormone.

Authors:  J Krishna
Journal:  Indian J Pediatr       Date:  1997 Mar-Apr       Impact factor: 1.967

2.  Skeletal size and bone mineral content in Turner's syndrome: relation to karyotype, estrogen treatment, physical fitness, and bone turnover.

Authors:  R W Naeraa; K Brixen; R M Hansen; C Hasling; L Mosekilde; J H Andresen; P Charles; J Nielsen
Journal:  Calcif Tissue Int       Date:  1991-08       Impact factor: 4.333

3.  Plasma GH responses to GHRH, arginine, L-dopa, pyridostigmine, sequential administrations of GHRH and combined administration of PD and GHRH in Turner's syndrome.

Authors:  K Hanew; A Tanaka; A Utsumi
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

4.  Response to three years of growth hormone therapy in girls with Turner syndrome.

Authors:  Hong Kyu Park; Hae Sang Lee; Jung Hee Ko; Il Tae Hwang; Jin Soon Hwang
Journal:  Ann Pediatr Endocrinol Metab       Date:  2013-03-31

5.  Turner syndrome.

Authors:  C G Brook
Journal:  Arch Dis Child       Date:  1986-03       Impact factor: 3.791

6.  Methionyl human growth hormone in Turner's syndrome.

Authors:  C Rongen-Westerlaken; J M Wit; S L Drop; B J Otten; W Oostdijk; H A Waal; M H Gons; A Bot; J L Van den Brande
Journal:  Arch Dis Child       Date:  1988-10       Impact factor: 3.791

7.  Sex chromosome aberrations and stature: deduction of the principal factors involved in the determination of adult height.

Authors:  T Ogata; N Matsuo
Journal:  Hum Genet       Date:  1993-07       Impact factor: 4.132

8.  Effect of obesity on endogenous secretion of growth hormone in Turner's syndrome.

Authors:  P W Lu; C T Cowell; M Jimenez; J M Simpson; M Silink
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

9.  Growth hormone treatment of Turner syndrome patients with insufficient growth hormone response to pharmacological stimulation tests.

Authors:  G Massa; M Vanderschueren-Lodeweyckx; M Craen; M Vandeweghe; G van Vliet
Journal:  Eur J Pediatr       Date:  1991-05       Impact factor: 3.183

10.  Recombinant human growth hormone in the treatment of Turner syndrome.

Authors:  Bessie E Spiliotis
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.